Drug General Information (ID: DDIHCM9O47)
Drug Name			Norgestimate		Drug Info		Calaspargase pegol		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Contraceptive Agents				Antineoplastics

Mechanism of Norgestimate-Calaspargase pegol Interaction (Severity Level: Moderate)
Decreased metabolism due to hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Norgestimate				Calaspargase pegol
Mechanism		Metabolized by the liver				Hepatotoxicity
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Drug-induced hepatotoxicity is an acute or chronic liver injury secondary to drugs. The metabolism of drugs is reduced when the liver is damaged and fewer enzymes are synthesized by the liver.
Mechanism Description		Decreased metabolism of Norgestimate caused by Calaspargase pegol mediated hepatotoxicity

Recommended Action
Management		The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.